Carl Icahn is ramping up pressure on Illumina to implement operational changes, emphasizing that its subsidiary Grail is draining over $800 million annually from the company. While Illumina faces these financial challenges, optimistic signs in the broader stock market and a stabilized banking sector provide a contrasting backdrop. Furthermore, Illumina's stock is expected to surge due to projected cost reductions, suggesting potential recovery avenues amidst ongoing shareholder scrutiny.
Click a month on the chart to update the report below.
.svg&width=160)